BNAD-101 is under clinical development by Bryleos and currently in Phase I for Substance (Drug) Abuse. According to GlobalData, Phase I drugs for Substance (Drug) Abuse have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BNAD-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BNAD-101 overview
BNAD-101 is under development for the treatment of chronic diseases of ageing and substance use disorder. The drug candidate comprises of nicotinamide adenine dinucleotide plus. It is administered through oral route.
Bryleos overview
Bryleos a biotechnology research company which focuses on clinical stage therapeutics for commercializing in the development of BNAD101 and offers aging and common age-related diseases. Bryleos is headquartered in Knoxville, Tennessee, the US.
For a complete picture of BNAD-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.